The company has announced the appointment of Klaus Edvardsen as Chief Development Officer.
“I am very pleased to welcome Klaus to Nykode Therapeutics’ executive management team. Klaus brings tremendous international leadership experience in directing successful drug development programs at renowned biopharmaceutical companies. As Nykode’s candidates continue to advance through the clinical, we are eager for Klaus’ significant contributions to our drug development strategies,” says Chief Executive Officer of Nykode Therapeutics, Michael Engsig.
The appointment took effect on July 1, 2022.
Klaus Edvardsen joins Nykode from CureVac where he held a similar role as Chief Development Officer. Other previous roles include Senior Vice President and Head of Global Oncology Development of Merck KGaA, where he led early- and late-stage global oncology development. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca, where he was responsible for the overall development strategy for oncology and hematology programs. Klaus Edvardsen also held leadership roles at both GlaxoSmithKline and Genmab in medicines development within various therapeutic areas.
Klaus Edvardsen holds a M.D. degree as well as a Ph.D. in cancer biology from University of Copenhagen.
“I am very excited to be joining Nykode Therapeutics,” says Klaus Edvardsen. “Nykode has developed a unique platform technology and has entered into some impressive collaborations and partnerships with world-class biopharmaceutical companies. With its strong development pipeline, Nykode has built a great momentum on its quest to develop game changing medicines across an expanding range of therapeutic areas and I look forward to joining the team.”